Blog

Retatrutide Dosing Guide for Researchers

reta dosing guide

Retatrutide Dosing: A Research Protocol Reference This guide compiles dosing information, reconstitution procedures, and storage guidelines for retatrutide based on published clinical trial literature and standard peptide handling protocols. It is intended as a reference for researchers working with retatrutide…

Retatrutide Clinical Trials: 2026 Research Update

reta clinical trial update

Retatrutide Clinical Trials: Where We Stand in 2026 Retatrutide (LY3437943) has emerged as one of the most closely watched peptide compounds in metabolic research. Following landmark Phase 2 results published in The New England Journal of Medicine, the compound has…

Retatrutide vs Tirzepatide vs Semaglutide: Key Differences

Retatrutide vs Tirzepatide vs Semaglutide

Comparing Retatrutide, Tirzepatide, and Semaglutide The metabolic peptide research landscape has evolved rapidly with the development of multi-receptor agonists. While semaglutide established the foundation as a single GLP-1 receptor agonist, tirzepatide advanced the field with dual GLP-1/GIP agonism, and now…

What Is Retatrutide? Mechanism of Action Explained

What Is Retatrutide? Mechanism of Action Explained

What Is Retatrutide? Retatrutide (LY3437943) is a novel triple-agonist peptide developed by Eli Lilly that simultaneously activates three incretin-related receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This triple mechanism distinguishes retatrutide from dual-agonist compounds like tirzepatide…